Stock Evaluator: RetinalGenix Technologies Inc. (RTGN)

RetinalGenix Technologies Inc. RTGN

$3.99 0.00 0.00%
September 16, 2026 3:45:29 PM EST November 10, 2021 Volume: 0
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Equipment & Supplies

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. The company offers the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians. It also develops RTG-2023 for the treatment of dry age-related macular degeneration; and RTG-2024 for the treatment of Alzheimer’s syndrome dementia. The company was incorporated in 2017 and is based in Apollo Beach, Florida. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.

Commentary & Analysis


Financial Summary

Share Statistics RTGN Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $75.2 $389.6 19%
Shares Out (Mil) 18.8 40.9 29%
Institutional Ownership na 82.8% na
Float (Mil) na 35.5 na
Beta -3.32 0.85 0%
Avg Daily Volume (000s) 3 298 11%
Price Change
(52-week)
na 63.7% na
Growth RTGN Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 11.8% na
Net Income (5yr) (2.7%) (5.6%) 36%
EPS (5yr) (20.3%) 10.2% 13
Dividends (5yr) na 0.0% na
Cash Flow (5yr) 0.0% (15.5%) 64%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials RTGN Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $141 na
Net Income (TTM) (Mil) ($2) ($9) 36%
EPS (TTM) ($0.112) ($0.400) 36%
Operating Cash Flow (TTM) (Mil) ($1) ($2) 31%
Net Cash Flow (TTM) (Mil) na $1 na
Long-Term Debt (Q1) (Mil) $0 $26 0%
Enterprise Value (Q1) (Mil) na $409 na
Valuation RTGN Industry
Median
Percentile
(All Stocks)
P/B na 2.73 na
P/E na 25.0 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.4 na
Ratios RTGN Industry
Median
Percentile
(All Stocks)
Gross Margin na 58.7% na
Net Margin na (6.9%) na
ROA na (12.2%) na
ROE 90.4% (10.7%) 96%
Liabilities to Assets na 47.2% na
F-Score 1 4 1%

RetinalGenix Technologies Inc. did not pass any screens on 10/2/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors